The Role of Circulating Tumor (ct)DNA Testing/Monitoring in Stage II-III Colorectal Cancer

February 15, 2021

Christopher Lieu, MD, Anschutz Medical Campus

, Sepideh Gholami, MD, FACS, UC Davis Comprehensive Cancer Center

Sepideh Gholami, MD, FACS, UC Davis Comprehensive Cancer Center

Two experts in the management of colorectal cancer discuss the evolving role of circulating tumor (ct)DNA testing/monitoring in stage II and III disease.

The Role of Circulating Tumor (ct)DNA Testing/Monitoring in Stage II-III Colorectal Cancer

Christopher Lieu, MD, Anschutz Medical Campus

Sepideh Gholami, MD, FACS, UC Davis Comprehensive Cancer Center

Dr. Kazmi on Differences Between Left- Versus Right-Sided CRC Tumors

Cologuard mt-sDNA Test Could Provide a Noninvasive Screening Option for CRC

Dr. Dasari on the Rationale for the FRESCO-2 Trial With Fruquintinib in mCRC